National Research Corporation (NRC) Stock | NRC Stock Price & Analysis

Feed

NRC

National Research Corporation NRC · NASDAQ

$21.93 +2.57% (+$0.55)

Summary

43 / 100 · Bulios Score

Valuation 26Growth 1Profitability 66Quality 69Debt 20Stability 79

What speaks for it

Out of every 100 USD of revenue, 15 USD is left as free cash.
It bought back its own shares for $20.2M in the last fiscal year, 4.3% of its market value.

What to watch

It pays out more in dividends than it earns: 242% of profit.
Earnings per share fell by 26% a year over the last 3 years.
The share price is above the Bulios Fair Price.
Repaying its net debt would take 3.7 years of operating profit.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Is it expensive?

Looks expensive

Bulios Fair Price

Current price $21.93

P/E today 80.7 183% higher

5-year average P/E 28.5

P/E today 80.7

Medical - Healthcare Information Services industry median

Unlock fair price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 80.7 USD for 1 USD of yearly profit. Over the last five years it was 28.5 USD on average.

Valuation in detail

Is it growing?

It is shrinking

Revenue (USD)

148M

152M

149M

143M

137M

118M

127M

2021202220232024202520262027

Diluted EPS (USD)

$1.46

$1.27

$1.25

$1.04

$0.52

$0.88

$1.11

2021202220232024202520262027

Analyst estimate

Revenue grew by 0.6% a year over 5 years. Over the last 3 years it fell by 3.2% a year. Earnings per share fell by 26% a year over the last 3 years.

Growth in detail

Does it make money?

Reasonably

Where 100 USD of revenue goes

Cost of sales 33 USD
Sales and administration 56 USD
Taxes and other 6.3 USD
Net profit 4.2 USD

Net profit, industry median (Medical - Healthcare Information Services) 4.7 USD

Out of every 100 USD of revenue, 4.2 USD is left as net profit.

Profitability in detail

Is it financially healthy?

Mostly

Cash and short-term investments $3.33M

Debt $90.0M

Free cash flow over 12 months $21.6M

Repaying all its debt would take 4.2 years of free cash flow. Its debt is larger than its cash.

Financial health in detail

Does it pay a dividend?

Moderate, at risk

0.48

0.84

1.48

0.48

0.52

20212022202320242025

Yield: 2.99%
Paid out of profit: 242%
Raised in a row: 1 year

You receive $0.64 per share a year. The payout is more than the company can comfortably cover.

Dividends in detail

What do analysts expect?

Mildly positive

Buy 1
Hold 0
Sell 0

No analyst has published a price target.

100% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2024

By product

The company reports no revenue by product.

By region

UNITED STATES 100%

UNITED STATES brings in 100% of revenue.

Segments in detail